Marzeptacog alfa

N/A

Report date: 2025/06/17 20:00:11

Base Information

Drug NameMarzeptacog alfa
Drug Alias NameMarzeptacog alphamarzeptacog alfa (activated)Recombinant Factor VIIa variant (813d) - PfizerFVIIaMarzAA +[10] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionCoagulation factor IX stimulantsCoagulation factor X stimulantsBlood coagulation pathway activation +[4] 
TargetsCoagulation factor IXCoagulation factor X
Therapy Area/IndicationsHemophilia BHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumArmeniaBulgaria +[19] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCatalyst
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGC Biopharma CorpCatalyst Biosciences IncWyeth Pharmaceuticals LLC
Active IndicationsN/A
Inactive IndicationsHemophilia BHemophilia A

Other Information

ATC CodeN/A
Related LinksN/A